Immunohistochemical and bioinformatics analysis of the placental BCL-2 and Beclin-1 expressions in preeclampsia and HELLP syndrome

被引:0
|
作者
Oglak, Suleyman Cemil [1 ]
Asir, Firat [2 ]
Yilmaz, Emine Zeynep [3 ]
Asir, Aysegul [4 ]
Bolluk, Gokhan [5 ]
Korak, Tugcan [6 ]
Ayaz, Hayat [2 ]
Agacayak, Elif [7 ]
机构
[1] Hlth Sci Univ, Gazi Yasargil Training & Res Hosp, Dept Obstet & Gynaecol, Diyarbakir, Turkiye
[2] Dicle Univ, Fac Med, Dept Histol & Embryol, Diyarbakir, Turkiye
[3] Bahcelievler Mem Hosp, Dept Obstet & Gynaecol, Istanbul, Turkiye
[4] Hlth Sci Univ, Gazi Yasargil Training & Res Hosp, Dept Pediat, Diyarbakir, Turkiye
[5] Basaksehir Cam & Sakura City Hosp, Dept Perinatol, Istanbul, Turkiye
[6] Kocaeli Univ, Fac Med, Dept Med Biol, Kocaeli, Turkiye
[7] Dicle Univ, Fac Med, Dept Obstet & Gynaecol, Diyarbakir, Turkiye
关键词
Preeclampsia; HELLP syndrome; placenta; apoptosis; autophagy; bioinformatics; PREGNANT-WOMEN; AUTOPHAGY; BAX;
D O I
10.1080/01443615.2025.2478577
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background This study aimed to examine the alterations in apoptosis and autophagy in placental tissues from normal pregnancies compared to those affected by preeclampsia (PE) and HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. We analysed the expression of autophagy-associated proteins, Beclin-1 and BCL-2, in human placental tissues and assessed their variations in placentas from pregnancies complicated by PE and HELLP syndrome by immunohistochemical (IHC) and in silico analyses. Methods An experimental case-control study was performed, involving 40 pregnant women complicated with preeclampsia, 25 pregnant women with HELLP syndrome, and 40 healthy pregnant women. The placental sections were stained with BCL-2 and Beclin-1 immunostains and subjected to IHC examination. The results of the IHC staining were assessed using semi-quantitative analysis. In silico analyses were performed using STRING and Cytoscape software to construct protein interaction networks for BCL-2 and Beclin-1 in PE and HELLP syndrome, followed by Gene Ontology analysis of common interactors to identify significant biological pathways. Results Both BCL-2 expression was significantly decreased (p < 0.001 and p < 0.0001, respectively) and Beclin-1 staining was significantly increased (p < 0.0001 and p < 0.0001, respectively) in the PE group and HELLP group compared to the control group. The changes in BCL-2 and Beclin-1 expression between PE and the HELLP group were also statistically significant. BCL2 expression was notably lower (p < 0.0001), and Beclin-1 staining was significantly higher (p < 0.05) in the HELLP group compared to the PE group. In PE, BCL-2 interactors were enriched in apoptosis, cytokine production, and cell proliferation pathways, while Beclin-1 interactors were linked to autophagy and phosphatidylinositol-mediated signalling. In HELLP, BCL-2 interactors were involved in inflammatory response regulation, whereas Beclin-1 interactors were associated with vascular endothelial growth factor (VEGF) signalling and immune regulation. Conclusions The differential expression patterns of BCL-2 and Beclin-1 between the PE and HELLP groups suggest that these proteins play distinct roles in the pathophysiology of these conditions.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Differential interactions between Beclin 1 and bcl-2 family members
    Erlich, Shlomit
    Mizrachy, Liat
    Segev, Oshik
    Lindenboim, Liora
    Zmira, Ofir
    Adi-Harel, Sheli
    Hirsch, Joel A.
    Stein, Reuven
    Pinkas-Kramarski, Ronit
    AUTOPHAGY, 2007, 3 (06) : 561 - 568
  • [32] Structural insights for selective disruption of Beclin 1 binding to Bcl-2
    Pan, Yun-Zu
    Liang, Qiren
    Tomchick, Diana R.
    De Brabander, Jef K.
    Rizo, Josep
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [33] Relationship between bcl-2, bax, beclin-1, and cathepsin-D proteins during postovulatory follicular regression in fish ovary
    Morais, Roberto D. V. S.
    Thome, Ralph G.
    Santos, Helio B.
    Bazzoli, Nilo
    Rizzo, Elizete
    THERIOGENOLOGY, 2016, 85 (06) : 1118 - 1131
  • [34] 18α-Glycyrrhetinic acid lethality for neuroblastoma cells via de-regulating the Beclin-1/Bcl-2 complex and inducing apoptosis
    Rahman, Md. Ataur
    Bishayee, Kausik
    Habib, Khadija
    Sadra, Ali
    Huh, Sung-Oh
    BIOCHEMICAL PHARMACOLOGY, 2016, 117 : 97 - 112
  • [35] Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death
    Park, Kyung-Jin
    Lee, Seung-Hyun
    Lee, Chang-Han
    Jang, Ji-Young
    Chung, Junho
    Kwon, Myung-Hee
    Kim, Yong-Sung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 382 (04) : 726 - 729
  • [36] 针刺通过恢复Beclin-1和Bcl-2的平衡抑制MCAO/R大鼠细胞凋亡研究
    江姗姗
    吕倩忆
    郑慧娥
    何灏龙
    唐红
    汪红娟
    陈楚淘
    田浩梅
    时珍国医国药, 2023, 34 (04) : 1003 - 1007
  • [37] The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: A tissue microarray study
    Baspinar, Sirin
    Bircan, Sema
    Orhan, Hikmet
    Kapucuoglu, Nilgun
    Bozkurt, Kemal Kursat
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (07) : 412 - 418
  • [38] Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway
    Sheng Zhang
    Xue-Hong Gui
    Li-Ping Huang
    Min-Zhen Deng
    Ruo-Ming Fang
    Xue-Hong Ke
    Yu-Ping He
    Ling Li
    Yong-Qi Fang
    Molecular Neurobiology, 2016, 53 : 83 - 94
  • [39] Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway
    Zhang, Sheng
    Gui, Xue-Hong
    Huang, Li-Ping
    Deng, Min-Zhen
    Fang, Ruo-Ming
    Ke, Xue-Hong
    He, Yu-Ping
    Li, Ling
    Fang, Yong-Qi
    MOLECULAR NEUROBIOLOGY, 2016, 53 (01) : 83 - 94
  • [40] Anti-cell death engineering of CHO cells: Co-overexpression of Bcl-2 for apoptosis inhibition, Beclin-1 for autophagy induction
    Lee, Jae Seong
    Ha, Tae Kwang
    Park, Jin Hyoung
    Lee, Gyun Min
    BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (08) : 2195 - 2207